What is Rigel Pharmaceuticals's D&A?

Rigel Pharmaceuticals (RIGL) reported D&A of $597K in Q1 2026.

How has Rigel Pharmaceuticals's D&A changed year-over-year?

Rigel Pharmaceuticals's D&A decreased by 1.2% year-over-year, from $604K to $597K.

What is the long-term trend for Rigel Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Rigel Pharmaceuticals's D&A has grown at a 20.1% compound annual growth rate (CAGR), from $1.16M to $2.42M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Rigel Pharmaceuticals RIGL D&A

D&A at other companies

AmgenAMGN

$1.12B-19.5%

Agios PharmaceuticalsAGIO

$1.36M+6.7%

Nuvation BioNUVB

$536K+72.9%

RegenxbioRGNX

$3.86M-2.5%

Zevra Therapeutics, Inc.ZVRA

$368K-77.7%

Gyre Therapeutics, Inc.GYRE

$672K+25.6%

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's D&A?: Rigel Pharmaceuticals (RIGL) reported D&A of $597K in Q1 2026.
How has Rigel Pharmaceuticals's D&A changed year-over-year?: Rigel Pharmaceuticals's D&A decreased by 1.2% year-over-year, from $604K to $597K.
What is the long-term trend for Rigel Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Rigel Pharmaceuticals's D&A has grown at a 20.1% compound annual growth rate (CAGR), from $1.16M to $2.42M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.